Figure 6.
Effects of the MEK inhibitor U0126 (10 µM) on PMA (100 nM) versus sorafenib (0.1 µM)-induced ERK-1/2 phosphorylation in different human bladder carcinoma cell lines (RT4, T24, J82). Original photographs and the quantitative analysis (means ± SEM) of five experiments are shown. *P < 0.05 versus control (anova /Bonferroni).